GlassScriptPhysician profile
Anahi P Munoz
NPI 1376918631
$2,750.90
in general payments reported to CMS, 2019-2025
18 companies · $52.75 in 2025
The $52.75 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.60 · 2021: $813 · 2022: $638 · 2023: $671 · 2024: $561 · 2025: $52.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $683.07 | 2022-2024 | Azstarys, Azstarys |
| Abbvie INC. | $361.81 | 2021-2023 | |
| Almatica Pharma LLC | $260.44 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $249.06 | 2021-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $241.78 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $234.83 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $172.15 | 2021-2022 | |
| Bausch Health US, LLC | $112.42 | 2022-2023 | Aplenzin |
| Neurocrine Biosciences, INC. | $97.56 | 2024-2025 | Ingrezza |
| Adlon Therapeutics L.P. | $75.67 | 2021 | |
| Alkermes, INC. | $59.73 | 2021-2023 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $46.84 | 2023-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $44.72 | 2023-2024 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $40.24 | 2023-2024 | Quviviq |
| Tris Pharma INC | $25.50 | 2023 | Dyanavel Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $15.60 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.37 | 2022 | |
| Neos Therapeutics, LP | $14.11 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anahi Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.